Literature DB >> 26020482

Symptom Profiles in Patients With Irritable Bowel Syndrome or Functional Abdominal Pain Compared With Healthy Controls.

James W Varni1, Robert J Shulman, Mariella M Self, Samuel Nurko, Miguel Saps, Shehzad A Saeed, Cristiane B Bendo, Ashish S Patel, Chelsea Vaughan Dark, George M Zacur, John F Pohl.   

Abstract

OBJECTIVES: Patient-reported outcome (PRO) measures of gastrointestinal symptoms are recommended to determine treatment effects for irritable bowel syndrome (IBS) and functional abdominal pain (FAP). Study objectives were to compare the symptom profiles of pediatric patients with IBS or FAP with healthy controls and with each other using the PedsQL Gastrointestinal Symptoms and Gastrointestinal Worry Scales, and to establish clinical interpretability of PRO scale scores through identification of minimal important difference (MID) scores.
METHODS: Gastrointestinal Symptoms and Worry Scales were completed in a 9-site study by 154 pediatric patients and 161 parents (162 families; IBS n = 46, FAP n = 119). Gastrointestinal Symptoms Scales measuring stomach pain, stomach discomfort when eating, food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea were administered along with Gastrointestinal Worry Scales. A matched sample of 447 families with healthy children completed the scales.
RESULTS: Gastrointestinal Symptoms and Worry Scales distinguished between patients with IBS or FAP compared with healthy controls (P < 0.001), with larger effect sizes (>1.50) for symptoms indicative of IBS or FAP, demonstrating a broad multidimensional gastrointestinal symptom profile and clinical interpretability with MID scores for individual PRO scales. Patients with IBS manifested more symptoms of constipation, gas and bloating, and diarrhea than patients with FAP.
CONCLUSIONS: Patients with IBS or FAP manifested a broad gastrointestinal symptom profile compared with healthy controls with large differences, indicating the critical need for more effective interventions to bring patient functioning within the range of healthy functioning.

Entities:  

Mesh:

Year:  2015        PMID: 26020482     DOI: 10.1097/MPG.0000000000000795

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  12 in total

1.  Evaluation of FODMAP Carbohydrates Content in Selected Foods in the United States.

Authors:  Bruno P Chumpitazi; Jongbin Lim; Ann R McMeans; Robert J Shulman; Bruce R Hamaker
Journal:  J Pediatr       Date:  2018-04-26       Impact factor: 4.406

2.  Increased Gut Permeability in First-degree Relatives of Children with Irritable Bowel Syndrome or Functional Abdominal Pain.

Authors:  Mark McOmber; Danny Rafati; Kevin Cain; Sridevi Devaraj; Erica M Weidler; Margaret Heitkemper; Robert J Shulman
Journal:  Clin Gastroenterol Hepatol       Date:  2019-05-14       Impact factor: 11.382

3.  PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity.

Authors:  Kavitha Nutakki; James W Varni; Nancy L Swigonski
Journal:  J Neurooncol       Date:  2017-12-22       Impact factor: 4.130

4.  Gastrointestinal symptoms predictors of health-related quality of life in pediatric patients with functional gastrointestinal disorders.

Authors:  James W Varni; Robert J Shulman; Mariella M Self; Samuel Nurko; Miguel Saps; Shehzad A Saeed; Ashish S Patel; Chelsea Vaughan Dark; Cristiane B Bendo; John F Pohl
Journal:  Qual Life Res       Date:  2016-10-14       Impact factor: 4.147

5.  Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial.

Authors:  Robert J Shulman; Emily B Hollister; Kevin Cain; Danita I Czyzewski; Mariella M Self; Erica M Weidler; Sridevi Devaraj; Ruth Ann Luna; James Versalovic; Margaret Heitkemper
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-11       Impact factor: 11.382

6.  Perceived medication adherence barriers mediating effects between gastrointestinal symptoms and health-related quality of life in pediatric inflammatory bowel disease.

Authors:  James W Varni; Robert J Shulman; Mariella M Self; Shehzad A Saeed; George M Zacur; Ashish S Patel; Samuel Nurko; Deborah A Neigut; James P Franciosi; Miguel Saps; Jolanda M Denham; Chelsea Vaughan Dark; Cristiane B Bendo; John F Pohl
Journal:  Qual Life Res       Date:  2017-09-08       Impact factor: 4.147

7.  Fructans Exacerbate Symptoms in a Subset of Children With Irritable Bowel Syndrome.

Authors:  Bruno Pedro Chumpitazi; Ann Rhodes McMeans; Adetola Vaughan; Amna Ali; Shannon Orlando; Ali Elsaadi; Robert Jay Shulman
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-29       Impact factor: 11.382

8.  Assessment of the gut bacterial microbiome and metabolome of girls and women with Rett Syndrome.

Authors:  Santosh Thapa; Alamelu Venkatachalam; Nabeel Khan; Mohammed Naqvi; Miriam Balderas; Jessica K Runge; Anthony Haag; Kathleen M Hoch; Daniel G Glaze; Ruth Ann Luna; Kathleen J Motil
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

9.  Associations of Abdominal Pain and Psychosocial Distress Measures With Health-Related Quality-of-Life in Pediatric Healthy Controls and Irritable Bowel Syndrome.

Authors:  John M Hollier; Danita I Czyzewski; Mariella M Self; Yan Liu; Erica M Weidler; Miranda A L van Tilburg; James W Varni; Robert J Shulman
Journal:  J Clin Gastroenterol       Date:  2021 May-Jun 01       Impact factor: 3.174

10.  Long-Term Study of Children With ROME III Functional Gastrointestinal Disorders Managed Symptomatically in a Biopsychosocial Model.

Authors:  Shailender Madani; Suchi Parikh; Rohit S Madani; Amornluck Krasaelap
Journal:  Gastroenterology Res       Date:  2017-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.